Lemercier Jean-Luc M's Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 9, 2023
- Accession no.
- 0001225208-23-005617
- Filed
- May 9, 2023
- Trade date
- May 7-9, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $588.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lemercier Jean-Luc MCIK 0001710625 | Officer (CVP, EMEACLA and JAPAC) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2023 | Common Stock | MOption exerciseAcquired | +3,355 | $0.00F1 | $0 | 172,417.78 | Direct | |
| May 7, 2023 | Common Stock | FTax withholdingDisposed | −224 | $88.74 | −$19,877.76 | 172,193.78 | Direct | |
| May 8, 2023 | Common Stock | FTax withholdingDisposed | −104 | $88.74 | −$9,228.96 | 172,089.78 | Direct | |
| May 9, 2023 | Common Stock | MOption exerciseAcquired | +6,640 | $35.20 | +$233,728 | 178,729.78 | Direct | |
| May 9, 2023 | Common Stock | SSaleDisposed | −6,640 | $88.68 | −$588,835.2 | 172,089.78 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2023 | Common Stock | MOption exerciseDisposed | −3,355 | $0.00 | $0 | 920 | Direct | |
| May 9, 2023 | Common Stock | MOption exerciseDisposed | −6,640 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.